Sg Americas Securities, LLC Kazia Therapeutics LTD Transaction History

Sg Americas Securities, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 29, 2022	SELL	$4.1 - $8.38 $40,635 - $83,054	-9,911 Reduced 41.47%	13,988 $59,000
Q1 2022 Apr 29, 2022	SELL	$6.05 - $8.65 $61,752 - $88,290	-10,207 Reduced 29.93%	23,899 $184,000
Q4 2021 Feb 07, 2022	SELL	$7.35 - $12.0 $41,674 - $68,040	-5,670 Reduced 14.25%	34,106 $288,000
Q3 2021 Nov 01, 2021	SELL	$8.65 - $11.64 $39,980 - $53,800	-4,622 Reduced 10.41%	39,776 $450,000
Q2 2021 Aug 12, 2021	BUY	$9.1 - $14.71 $43,516 - $70,343	4,782 Added 12.07%	44,398 $438,000
Q1 2021 May 13, 2021	BUY	$8.98 - $12.86 $355,751 - $509,461	39,616 New	39,616 $491,000

2.13M

93.2K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $87.5M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.